Susan Dillon is the founder of Aro Biotherapeutics. Aro Biotherapeutics has raised $42M in total funding. Latest round: Series B. Based in Philadelphia, USA.
Susan Dillon is the Chief Executive Officer of Aro Biotherapeutics, a clinical-stage biotechnology company located in Philadelphia. Aro Biotherapeutics specializes in developing tissue-targeted genetic medicines, leveraging its proprietary Centyrin platform. The company recently secured $41.5 million in Series B financing to advance its pipeline, including its lead program ABX1100 for Pompe Disease.
Full founder directory · Investor directory · Company funding database · Fundraising library